BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

10.80B

Market cap10.80B

Price-Earnings ratio

152.17

Price-Earnings ratio152.17

Dividend yield

—

Dividend yield—

Average volume

2.62M

Average volume2.62M

High today

$57.00

High today$57.00

Low today

$55.55

Low today$55.55

Open price

$56.40

Open price$56.40

Volume

806.24K

Volume806.24K

52 Week high

$70.98

52 Week high$70.98

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

BioMarin(BMRN) stock is priced at $55.82, giving the company a market capitalization of 10.8B. It carries a P/E multiple of 152.17.

On 2026-10-21, BioMarin(BMRN) stock traded between a low of $55.55 and a high of $57.00. Shares are currently priced at $55.82, which is +0.5% above the low and -2.1% below the high.

BioMarin(BMRN) shares are trading with a volume of 806.24K, against a daily average of 2.62M.

In the last year, BioMarin(BMRN) shares hit a 52-week high of $70.98 and a 52-week low of $49.26.

BMRN News

TipRanks 5h

BioMarin price target lowered to $122 from $124 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on BioMarin (BMRN) to $122 from $124 and keeps an Overweight rating on the shares. Published first on TheFly – t...

Simply Wall St 1d

How New VOXZOGO Data At BioMarin Stock Has Changed Its Investment Story - Simply Wall Street

...

Simply Wall St 3d

BioMarin Pharmaceutical Flags 13 ASBMR Studies, Is It 25% Undervalued?

BioMarin Pharmaceutical (BMRN) just flagged a busy clinical calendar, with 13 study readouts on deck at ASBMR 2026 and fresh regulatory moves around VOXZOGO in...

Analyst ratings

77%

of 31 ratings

Buy

77.4%

Hold

22.6%

Sell

More BMRN News

TipRanks 7d

BioMarin assumed with a Buy at UBS

UBS analyst Joon Lee assumed coverage of BioMarin (BMRN) with a Buy rating and $88 price target The firm views the company as a turnaround story. Management cha...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.